Management of Intermediate-Risk Pulmonary Embolism

Immediate Anticoagulation Strategy

The European Society of Cardiology recommends starting unfractionated heparin (UFH) immediately without waiting for diagnostic confirmation if clinical probability is high or intermediate, as delay increases mortality risk in intermediate-risk PE 1, 2
UFH is the preferred initial agent over low molecular weight heparin (LMWH) in patients with severe renal impairment because it does not accumulate and can be rapidly reversed if bleeding occurs 1, 2
Administer an initial bolus of 80 U/kg IV followed by continuous infusion at 18 U/kg/h, adjusting based on aPTT to maintain 1.5-2.5 times control value 3

The European Society of Cardiology does not recommend routine administration of systemic thrombolysis to patients with intermediate-risk PE, as this is a Class III recommendation reserved strictly for high-risk PE with hemodynamic instability 1, 2, 4
Thrombolysis is only indicated if the patient develops hemodynamic deterioration (systolic BP <90 mmHg or cardiogenic shock requiring vasopressors) while on anticoagulation 1, 2

The American Society of Clinical Oncology recommends transitioning to therapeutic-dose LMWH once renal function permits (typically when creatinine clearance >30 mL/min), as LMWH is the preferred initial and long-term treatment specifically for cancer patients with PE 4, 3
LMWH options include dalteparin or enoxaparin at therapeutic fixed doses based on body weight 3
Continue LMWH indefinitely or until cancer is cured, as cancer-associated thrombosis has the highest recurrence risk 4

Intermediate-risk PE is defined by hemodynamic stability (systolic BP ≥90 mmHg) with evidence of right ventricular dysfunction on echocardiography or CT, or elevated cardiac biomarkers (troponin, BNP) 2, 4, 3
Monitor closely for signs of hemodynamic deterioration requiring escalation to thrombolysis: persistent hypotension, cardiogenic shock, or need for vasopressors 2, 4

The International Society on Thrombosis and Haemostasis recommends continuing anticoagulation indefinitely for cancer-associated PE, as this represents unprovoked VTE with ongoing risk factors 4, 3
Reassess drug tolerance, adherence, hepatic and renal function, and bleeding risk at regular intervals during extended anticoagulation 1, 4